Yokohama, Japan
Yokohama, Japan

Keio University , abbreviated as Keio or Keidai , is a Japanese university located in Minato, Tokyo. It is known as the oldest institute of higher education in Japan. Founder Fukuzawa Yukichi originally established it as a school for Western studies in 1858 in Edo . It has eleven campuses in Tokyo and Kanagawa. It has ten faculties: Letters, Economics, Law, Business and Commerce, Medicine, Science and Technology, Policy Management, Environment and Information Studies, Nursing and Medical Care, and Pharmacy.The alumni include Japanese prime ministers and prominent political, administrative, legal, medical and corporate leaders. In particular, alumni of the Faculty of Economics has had significant influence on Japanese business world. Keio ranks third in the world for the number of alumni holding CEO positions in Fortune Global 500 companies. It also ranks 9th in the world in the Times Higher Education's Alma Mater Index. The university is one of the Japanese Ministry of Education, Culture, Sports, Science and Technology's thirteen "Global 30" Project universities. Wikipedia.


Time filter

Source Type

Patent
Keio University | Date: 2016-09-29

In accordance with the disclosed semiconductor chip and multi-chip module, signal transmission is made possible between semiconductor chips that are placed on a plane so as to be adjacent to each other through inductive coupling without affecting other coils such as in an oscillation circuit or an antenna circuit for RF communication. A multilayer solenoid coil, where a plane of the coil formed in a multilayer wiring structure in a semiconductor body is parallel to a main surface of the semiconductor body, is formed along at least one side end surface of the semiconductor body.


Patent
TOAGOSEI Co. and Keio University | Date: 2016-09-29

The composition for producing neural stem cells provided by the present invention contains an artificially synthesized synthetic peptide having a neural stem cell-inducing peptide sequence that induces neural stem cells from fibroblasts, and one or two or more pharmaceutically acceptable carriers. The neural stem cell-inducing peptide sequence is any of (i) an amino acid sequence constituting a signal peptide of any protein belonging to the amyloid precursor protein (APP) family, (ii) a partial amino acid sequence of the amino acid sequence of (i), and (iii) a modified amino acid sequence of the amino acid sequence of (i) or (ii).


Patent
Keio University and Chugai Seiyaku Kabushiki Kaisha | Date: 2017-03-01

The present inventors focused on the fact that inflammation at the subretinal macular area enhances choroidal neovascularization, and developed pharmaceutical agents that suppress initiation or advancement of neovascularization by angiogenic factors such as VEGF. More specifically, the present inventors revealed that administering anti-IL-6 receptor monoclonal antibodies to mice treated with laser photocoagulation inhibits the development of choroidal neovascularization.


Patent
Keio University and Kabushiki Kaisha Yakult Honsha | Date: 2017-03-08

To provide a marker for determining sensitivity to an anti-cancer agent, which can determine whether or not a patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. The marker for determining sensitivity to an anti-cancer agent is formed of one or more substances selected from the group consisting of an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, lauric acid, 6-phosphogluconic acid, butyric acid, 4-methylpyrazole, isobutylamine, glycolic acid, NADH, NAD^(+), and a substance involved in the metabolism of any of these substances.


Patent
Keio University and Kabushiki Kaisha Yakult Honsha | Date: 2017-03-22

To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker. The marker for determining sensitivity to an anti-cancer agent is formed of one or more substances selected from the group consisting of a substance or a fragment thereof detected as an anion at m/z of 149.05 to 149.06, a substance or a fragment thereof detected as an anion at m/z of 152.99 to 153.00, a substance or a fragment thereof detected as a cation at m/z of 724.34 to 724.35, the peaks being determined by means of a mass spectrometer, glycerol 3-phosphate, dihydrobiopterin, GABA, lactic acid, asparagine, aspartic acid, 2-methylbutyroylcarnitine, 1-methyladenosine, and glutathione, and a substance involved in a metabolic pathway of any of these substances.


The present invention is directed to provide cancer stem cell proliferation inhibitors and inducers of intracellular accumulation of reactive oxygen species. To this end, provided are cancer stem cell proliferation inhibitors and inducers of intracellular accumulation of reactive oxygen species in a cancer stem cell each containing pimozide or sertindole as an active ingredient.


Patent
Toagosei Co., Keio University and Nagoya University | Date: 2017-04-26

Provided are a synthetic peptide that induces the reprogramming of a differentiated cell, a reprogramming-inducing pharmaceutical composition that contains this synthetic peptide, and a method for producing an undifferentiated cell from a differentiated cell using this synthetic peptide. The peptide provided by the present invention is a synthetic peptide having a reprogramming-inducing peptide sequence formed of the amino acid sequence given by SEQ ID NO: 1 or a modified amino acid sequence thereof. The method for producing an undifferentiated cell provided by the present invention includes inducing the reprogramming of a target cell by culturing a cell culture which contains the target cell and to which the synthetic peptide has been supplied.


Patent
Keio University | Date: 2017-06-14

In order to provide a gene expression enhancer for enhancing expression of FoxP3 gene in a cell; a cell differentiation inducer for inducing differentiation of a cell into a regulatory T cell; an immunosuppressor for suppressing immunity and an agent for treating hyperimmune diseases based on the abovementioned actions; an inhibitor of enhancement of gene expression for inhibiting enhancement of expression of FoxP3 gene in a cell; an inhibitor of induction of cell differentiation for inhibiting induction of differentiation of a cell into a regulatory T cell; a reducer of immunosuppression for reducing immunosuppression, a stimulator of tumor immunity and an antitumor agent based on the abovementioned actions; and the like, for example, an agent containing at least one of a cell expressing Snail protein, MCP1 protein, FSTL1 protein, membrane IL-13Ra2 protein or secretory IL-13Ra2 protein, or MCP1 protein, FSTL1 protein or secretory IL-13Ra2 protein, is used as a gene expression enhancer for FoxP3, an inducer of regulatory T cell differentiation, an immunosuppressor or an agent for treating hyperimmune diseases; and an agent containing an anti-MCP1 antibody, an anti-FSTL1 antibody or an anti-IL-13Ra2 antibody is used as an inhibitor of enhancement of FoxP3 gene expression, a reducer of immunosuppression, a stimulator of tumor immunity, an antitumor agent, or the like.


A pharmaceutical composition for prophylaxis and/or treatment of a corneal and conjunctival disease or presbyopia, the composition containing a compound represented by Formula (I), or a salt thereof or a prodrug thereof as an active ingredient,


Patent
Keio University and Kabushiki Kaisha Yakult Honsha | Date: 2017-07-05

A novel marker for determining sensitivity to an anti-cancer agent is provided. Disclosed is a marker for determining sensitivity to an anti-cancer agent including one or more molecules selected from the group consisting of PHB, ANXA5, ANXA1, TALDO, C1QBP, IPYR, CRBP1 and COX5A.

Loading Keio University collaborators
Loading Keio University collaborators